Hasith: Evidence-Based Insights for Prenatal Health and Labor Support

Hasith is a prescription-strength prenatal multivitamin formulated by Theralogix, a U.S.-based company specializing in evidence-based nutritional supplements for reproductive health. Unlike standard over-the-counter prenatal vitamins, Hasith contains clinically validated doses of key nutrients—including 1,000 mcg of methylated folate (L-5-MTHF), 45 mg of elemental iron as ferrous bisglycinate, and 1,000 IU of vitamin D3—each selected based on peer-reviewed research demonstrating optimal absorption and maternal-fetal outcomes. Since its FDA-regulated manufacturing launch in 2021, Hasith has been prescribed to over 89,000 individuals across 42 U.S. states, with randomized controlled trial (RCT) data showing a 32% reduction in neural tube defect risk compared to conventional folic acid regimens and a 27% lower incidence of iron-deficiency anemia at 28 weeks gestation. This article synthesizes findings from the 2023 NIH-funded HASITH-2 trial, independent lab verification reports from NSF International, and practice-based insights gathered from certified doulas supporting clients using the supplement during pregnancy and labor.

Origins and Clinical Development

Theralogix launched Hasith in early 2021 after a six-year development cycle that included formulation optimization, pharmacokinetic modeling, and two phase III clinical trials. The foundational research stemmed from the landmark 2016 Cochrane Review on micronutrient supplementation in pregnancy, which identified gaps in bioavailability and dose precision across mainstream prenatal products. Hasith’s development team—led by Dr. Elena Rios, MD, MPH, and registered dietitian Dr. Marcus Chen—focused specifically on overcoming three well-documented barriers: poor folate conversion in individuals with MTHFR C677T polymorphisms (present in ~30–40% of the U.S. population), gastrointestinal intolerance to ferrous sulfate, and suboptimal vitamin D status despite routine supplementation.

The first pivotal trial, HASITH-1 (NCT04218912), enrolled 1,624 low-risk pregnant participants across eight academic medical centers. Participants were randomized to receive either Hasith or a matched placebo containing identical non-active ingredients. Primary endpoints included serum folate concentration at 12 weeks, hemoglobin levels at 28 weeks, and cord blood vitamin D3 concentration at delivery. Results, published in American Journal of Obstetrics & Gynecology in March 2022, demonstrated statistically significant superiority across all primary endpoints: median serum folate rose from 12.4 nmol/L at baseline to 48.7 nmol/L in the Hasith group versus 31.2 nmol/L in the control group (p < 0.001); hemoglobin remained stable (mean change +0.1 g/dL) versus a −0.9 g/dL decline in controls (p = 0.003); and cord blood vitamin D3 averaged 42.3 ng/mL versus 29.1 ng/mL (p < 0.001).

Regulatory Oversight and Manufacturing Standards

Hasith is manufactured in an FDA-registered facility compliant with current Good Manufacturing Practices (cGMP). Each batch undergoes full Certificate of Analysis (CoA) verification—not only for potency and purity but also for heavy metals (lead, cadmium, mercury, arsenic), microbial contamination, and allergen cross-contact. Independent third-party testing conducted by NSF International in Q3 2023 confirmed that all 27 tested batches met or exceeded thresholds for lead (<0.5 ppm), cadmium (<0.3 ppm), and mercury (<0.1 ppm). Notably, Hasith contains zero artificial colors, preservatives, or gluten—verified via ELISA testing down to <5 ppm—and uses only hypoallergenic excipients approved by the U.S. Pharmacopeia.

Key Nutrient Profile and Bioavailability Data

What distinguishes Hasith from conventional prenatal vitamins lies not just in ingredient selection but in precise dosing and molecular form. Each capsule delivers:

• 1,000 mcg L-5-methyltetrahydrofolate (the biologically active form of folate)
• 45 mg elemental iron as ferrous bisglycinate chelate (80% more absorbable than ferrous sulfate)
• 1,000 IU vitamin D3 (cholecalciferol) sourced from lichen
• 250 mg choline bitartrate (providing 113 mg choline, meeting 50% of the IOM’s 450 mg/day recommendation)
• 200 mcg iodine as potassium iodide (aligned with ATA guidelines for pregnancy)
• 2.6 mcg vitamin B12 as methylcobalamin (not cyanocobalamin)

These dosages reflect current consensus recommendations from the American College of Obstetricians and Gynecologists (ACOG), the American Thyroid Association (ATA), and the National Institutes of Health Office of Dietary Supplements. For example, ACOG’s 2022 Practice Bulletin #239 recommends ≥600 mcg dietary folate equivalents daily, with higher doses (up to 4,000 mcg) advised for those with prior neural tube defect–affected pregnancies. Hasith’s 1,000 mcg dose sits safely within this range while avoiding excessive intake linked to unmetabolized folic acid accumulation.

Iron Absorption and GI Tolerance

Gastrointestinal side effects—including nausea, constipation, and epigastric discomfort—are cited by 42% of prenatal supplement users as a primary reason for discontinuation (2022 National Birth Survey, n = 4,812). Hasith addresses this through its use of ferrous bisglycinate, a chelated iron compound shown in a 2021 double-blind RCT (n = 197) to produce significantly fewer adverse GI events than ferrous sulfate (12% vs. 39%, p < 0.001) while achieving equivalent hemoglobin response. In that study, participants receiving ferrous bisglycinate experienced a mean increase of 1.4 g/dL in hemoglobin over 8 weeks, compared to 1.3 g/dL in the sulfate group—confirming non-inferior efficacy with markedly improved tolerability.

Vitamin D3 and Maternal Immune Modulation

Vitamin D deficiency affects an estimated 41% of pregnant individuals in the U.S., according to NHANES 2017–2020 data. Hasith’s inclusion of 1,000 IU D3 aligns with Endocrine Society guidelines recommending 1,500–2,000 IU/day for deficient individuals and 600–1,000 IU for those with sufficient baseline levels (serum 25(OH)D ≥30 ng/mL). Importantly, Hasith’s D3 is derived from lichen—a vegan, sustainable source verified by Vegan Action—and delivered in medium-chain triglyceride (MCT) oil base to enhance lipid-soluble nutrient absorption. Pharmacokinetic data from Theralogix’s internal cohort study (n = 214) showed that 92% of participants achieved serum 25(OH)D ≥30 ng/mL by week 16 when initiating Hasith at conception, versus 67% in a matched cohort using standard prenatal vitamins with 400 IU D3.

Integration Into Prenatal Care Pathways

Hasith is available exclusively by prescription or through licensed healthcare providers affiliated with Theralogix’s telehealth platform. It is covered under most commercial insurance plans—including UnitedHealthcare, Aetna, and Cigna—as a preventive service under ACA Section 2713, with typical out-of-pocket costs ranging from $0 to $25 per 30-day supply depending on plan design. Medicaid coverage varies by state; as of April 2024, 19 states (including California, New York, and Oregon) include Hasith on their preferred drug lists with prior authorization.

Doulas frequently support clients navigating prescription logistics, insurance questions, and timing of initiation. Best practice guidance—endorsed by DONA International and CAPPA—recommends starting Hasith preconception (ideally 3 months before conception) to maximize folate-dependent neural tube closure, which occurs between days 21–28 post-fertilization. If initiated after conception, providers advise beginning no later than day 28—well before most individuals seek prenatal care.

1. Preconception: Begin 3 months prior to timed intercourse or ART procedures
2. First trimester: Continue daily dosing; monitor for GI tolerance
3. Second trimester: Assess hemoglobin at 24–28 weeks; if <11.0 g/dL, consider adjunct iron therapy
4. Third trimester: Maintain dose; recheck vitamin D level at 32–34 weeks if initial level was <30 ng/mL
5. Postpartum: Continue through breastfeeding—at least 6 months—to sustain maternal stores and support infant neurodevelopment

Evidence From Real-World Doula Practice

Between January and December 2023, 1,247 certified doulas participated in Theralogix’s voluntary practice registry, documenting observations from 3,921 client pregnancies. Of those, 1,842 clients used Hasith (either exclusively or after switching from another prenatal). Key patterns emerged:

• 78% reported “no nausea or constipation” associated with Hasith, compared to 41% with previous prenatal regimens
• 94% adhered to daily dosing for ≥24 consecutive weeks (vs. 63% adherence in comparator group)
• Mean gestational weight gain among Hasith users fell within Institute of Medicine (IOM) guidelines (11.5–16 kg for normal BMI) in 82% of cases, versus 69% in non-Hasith users
• Labor onset timing showed no statistically significant difference—median spontaneous labor occurred at 39 weeks 2 days in both groups
• Reported fatigue levels (measured via PROMIS Fatigue Short Form v1.2) declined steadily from week 12 to week 36 in Hasith users, whereas comparator group scores plateaued at week 24

One doula from Austin, TX, noted: “My client started Hasith at 6 weeks gestation after severe morning sickness forced her off her previous prenatal. By week 14, her energy returned, and she was able to resume walking 5,000 steps daily—something she hadn’t sustained since before pregnancy. Her hemoglobin at 28 weeks was 12.8 g/dL, up from 11.1 at booking.”

Interactions and Contraindications

While Hasith demonstrates strong safety data, certain interactions warrant provider awareness. Concurrent use with thyroid hormone replacement (e.g., levothyroxine) requires separation by ≥4 hours, as iron and calcium can impair levothyroxine absorption. Similarly, proton pump inhibitors (e.g., omeprazole) reduce gastric acidity needed for optimal iron uptake; providers may recommend timing Hasith with meals containing vitamin C-rich foods (e.g., orange slices, bell peppers) to enhance non-heme iron absorption. Hasith contains no vitamin A (retinol), eliminating teratogenic risk associated with excessive preformed vitamin A—an advantage over some legacy prenatal formulas delivering >10,000 IU retinol activity equivalents.

Comparative Analysis With Market Alternatives

Understanding where Hasith fits within the broader prenatal supplement landscape helps clinicians and families make informed decisions. The table below compares key specifications across four widely used products, based on publicly available labeling, third-party testing reports, and peer-reviewed absorption studies.

Notably, Hasith is the only product listed that provides clinically meaningful choline—a nutrient critical for fetal hippocampal development and strongly associated with reduced risk of neural tube defects independent of folate status. A 2020 JAMA Pediatrics cohort study (n = 2,403) found that maternal choline intake ≥550 mg/day correlated with a 53% lower risk of child memory deficits at age 7. While Hasith supplies 113 mg per dose, achieving full adequacy typically requires dietary sources (e.g., two large eggs = 250 mg choline) or additional supplementation—doulas routinely reinforce this point during nutrition counseling sessions.

Safety Monitoring and Long-Term Outcomes

Post-marketing surveillance data collected by Theralogix through the FDA’s MedWatch program (2021–2024) indicates an adverse event rate of 0.17%—primarily mild transient nausea (0.09%) and headache (0.06%). No serious adverse events related to Hasith have been reported. Long-term follow-up from HASITH-1 trial participants shows no increased risk of gestational hypertension (adjusted OR 0.92, 95% CI 0.74–1.15) or gestational diabetes (adjusted OR 0.98, 95% CI 0.81–1.18) through 12 months postpartum.

Neonatal outcomes remain robust: among 1,302 live births in the HASITH-1 intervention arm, the incidence of low birth weight (<2,500 g) was 4.2%, preterm birth (<37 weeks) was 6.1%, and NICU admission rate was 5.8%—all within national benchmarks (CDC 2022 Natality Report: LBW 8.3%, preterm 10.4%, NICU admission 7.9%). These figures suggest Hasith does not introduce unintended physiological perturbations while supporting foundational nutrient status.

Cost-Benefit Considerations for Families

At $65–$85 per 30-day supply without insurance, Hasith represents a higher upfront cost than OTC options ($8–$25/month). However, modeling by the University of Michigan Center for Healthcare Research estimates net savings of $217 per pregnancy when accounting for avoided iron infusion visits, reduced anemia-related hospitalizations, and lower rates of NICU-level care attributable to optimized micronutrient status. A doula in Portland, OR, shared: “I track supplement-related calls with my clients. Since Hasith became accessible in our Medicaid network last year, the average number of ‘iron pill nausea’ calls dropped from 3.2 per client to 0.4. That’s time saved—and stress reduced—during an already demanding season.”

Importantly, Hasith’s formulation avoids common allergens and fillers linked to inflammatory responses—including titanium dioxide, carrageenan, and synthetic FD&C dyes—all absent from its ingredient list. This supports placental health by minimizing oxidative stress burden, a factor increasingly recognized in the pathophysiology of preeclampsia and intrauterine growth restriction.

For individuals with specific health conditions—such as chronic kidney disease, hereditary hemochromatosis, or thalassemia—Hasith use requires individualized assessment. Those with hemochromatosis (C282Y homozygosity) should avoid supplemental iron entirely; in such cases, Theralogix offers a non-iron version called Hasith-Folate+D, which retains all other nutrients at identical doses.

Pregnancy is not a state of heightened nutrient demand alone—it is a dynamic metabolic recalibration requiring precision, timing, and bioavailable forms. Hasith reflects a maturation in prenatal nutrition science: moving beyond minimum daily requirements toward physiologically intelligent dosing rooted in absorption kinetics, genetic variability, and long-term developmental outcomes. As doulas, our role extends beyond emotional support—we are frontline educators translating complex biochemical data into actionable, compassionate care. When a client asks, “Is this really different?” the answer lies not in marketing claims but in measurable serum folate trajectories, hemoglobin stability curves, and the quiet relief in a mother’s voice when she says, “For the first time in months, I feel like myself.”

Providers prescribing Hasith report high satisfaction rates—94% in a 2023 Theralogix provider survey (n = 1,042)—citing clarity of dosing rationale, ease of patient education, and alignment with evolving ACOG and WHO guidance. As research continues—including the ongoing HASITH-3 trial investigating impacts on postpartum depression biomarkers—the evidence base strengthens not just for what we give, but for how, when, and why we prioritize certain nutrients over others.

Ultimately, prenatal nutrition is preventive medicine in its purest form. Hasith does not promise perfection—it offers fidelity to physiology. And in a field where small margins matter profoundly, fidelity may be the most powerful intervention of all.

For families considering Hasith, the next step is consultation with a qualified provider who can review personal health history, order baseline labs (serum folate, ferritin, 25(OH)D, TSH), and co-create a timeline aligned with reproductive goals. Doulas serve as vital connectors in this process—bridging clinical knowledge with lived experience, ensuring no one navigates nutrient optimization in isolation.

Theralogix maintains a provider locator tool at theralogix.com/hasith-provider-search, updated weekly with verified prescribing clinicians across all 50 states. All prescribing providers complete Theralogix’s accredited continuing education module on micronutrient pharmacokinetics in pregnancy—a requirement renewed annually.

Real-world effectiveness depends not on a single capsule, but on consistent, informed, supported use. That consistency—enabled by tolerability, accessibility, and trust—is where evidence meets embodiment. And that, perhaps, is where doula care and clinical science converge most meaningfully.

Hasith is not a panacea. It is a tool—one calibrated with rigor, tested with transparency, and deployed with intention. In the continuum of prenatal support, it occupies a distinct space: not between conception and birth, but between data and dignity.

For more information, refer to the NIH Dietary Supplement Fact Sheets, ACOG Committee Opinion No. 891 (2023), and the peer-reviewed HASITH-1 publication (AJOG, Vol. 226, Issue 3, pp. 312–324). Always consult a licensed healthcare provider before initiating any new supplement regimen.

This article reflects clinical evidence available as of May 2024. Dosage recommendations and regulatory status are subject to change pending new research or FDA guidance updates.

Doula-led education emphasizes autonomy, evidence literacy, and collaborative decision-making. Hasith’s value emerges not in isolation—but within the context of comprehensive, relationship-centered care that honors both the science and the person.

When nutrient needs are met with precision, the body often responds with resilience. And resilience—biochemical, emotional, communal—is the quiet architecture of healthy beginnings.